Quantum-Si Inc. (QSI) - Q2 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. Quantum-Si Inc. is a life sciences company developing a proprietary single-molecule detection platform for Next-Generation Protein Sequencing (NGPS). The company's primary product is the Platinum® NGPS instrument, along with associated reagents, software, and semiconductor chips. The company initiated a full commercial launch of the Platinum® instrument at the end of the first quarter of 2024.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $622 | $205 | $1,079 | $459 |
| Gross Profit | $354 | $78 | $623 | $202 |
| Gross Margin | 56.9% | 38.0% | 57.7% | 44.0% |
| Net Loss | $(23,099) | $(25,573) | $(42,573) | $(49,184) |
| Operating Cash Flow | — | — | $(41,761) | $(51,623) |
| Cash & Marketable Securities | $218.1 million (as of June 30, 2024) |
Balance Sheet Highlights: Total assets were $256.7 million as of June 30, 2024, down from $298.3 million at year-end 2023. Total liabilities were $23.5 million. The company reported an accumulated deficit of $538.2 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 203.4% quarter-over-quarter (Q2 2024 vs. Q2 2023) and 135.1% year-to-date, driven by the commercial launch of the Platinum® instrument and increased sales of consumables.
- Expense Reduction: Research and Development (R&D) expenses decreased 9.2% in Q2 and 22.1% YTD compared to the prior year, primarily due to restructuring activities in 2023 and reduced fabrication costs.
- Net Loss Improvement: Net loss narrowed by 9.7% in Q2 and 13.4% YTD, aided by lower operating expenses and a gain on the change in fair value of warrant liabilities ($0.8 million YTD gain vs. $0.1 million YTD gain in 2023).
- Inventory Write-downs: The company recorded $1.6 million in inventory write-downs during the first six months of 2024, classified within R&D expenses.
Outlook, Risks, and Management Commentary
- Liquidity: Management expects existing cash, cash equivalents, and marketable securities ($218.1 million) to fund operations for at least the next 12 months. The company anticipates negative operating cash flows until commercial scale is achieved.
- Financing: The company has a $150 million Shelf Registration Statement effective since August 2023, including an At-The-Market (ATM) offering for up to $75 million. No shares have been sold under the ATM offering to date.
- Legal Proceedings:
- Stockholder Litigation: A class action lawsuit (Farzad v. HighCape Capital) was filed in May 2024 alleging breach of fiduciary duty regarding the 2021 Business Combination. The outcome is not estimable.
- Contract Manufacturer Dispute: A former contract manufacturer filed a breach of contract claim in Minnesota (refiled from Texas). The company believes it has a meritorious defense.
- Lease Dispute: Ongoing litigation regarding a $9.1 million lease incentive for the New Haven, Connecticut facility.
- Risks: Key risks include the inability to raise future financing, delays in product commercialization, supply chain constraints, and the impact of global conflicts on material availability.
Investor Verification Checklist
- Runway Validation: Verify the sufficiency of the $218.1 million cash position against the projected burn rate, considering the company's expectation of negative operating cash flows.
- Revenue Quality: Assess the sustainability of the 203% revenue growth and the mix between one-time instrument sales versus recurring consumable/service revenue.
- Legal Exposure: Monitor the status of the Farzad stockholder litigation and the contract manufacturer dispute for potential financial impact or settlement costs.
- Inventory Health: Review the $1.6 million inventory write-downs and the total inventory balance ($4.9 million) for signs of obsolescence or demand mismatches.
- Warrant Liability: Note the volatility in the "Change in fair value of warrant liabilities" line item, which significantly impacts reported net loss but is non-cash.